

Lenvima Approval Status Worldwide (Country/ Region)

June, 2022

Thyroid cancer

Argentina	May-2019	Egypt	Mar-2021	Lebanon	Nov-2016	Poland	May-2015
Australia	Jan-2016	Estonia	May-2015	Liechtenstein	May-2015	Portugal	May-2015
Austria	May-2015	Finland	May-2015	Lithuania	May-2015	Qatar	Dec-2021
Bahrain	Dec-2019	France	May-2015	Luxembourg	May-2015	Romania	May-2015
Belgium	May-2015	Germany	May-2015	Macau	Sep-2015	Russia	Dec-2015
Bolivia	Dec-2021	Greece	May-2015	Malaysia	Nov-2016	Saudi Arabia	Dec-2019
Brazil	Aug-2016	Guatemala	Dec-2020	Malta	May-2015	Singapore	Apr-2016
Brunei	Dec-2018	Hong Kong	May-2016	Mexico	May-2016	Slovakia	May-2015
Bulgaria	May-2015	Hungary	May-2015	Morocco	Feb-2021	Slovenia	May-2015
Cambodia	Apr-2019	Iceland	May-2015	Myanmar	Nov-2018	South Africa	May-2020
Canada	Dec-2015	India	Jan-2017	Namibia	Mar-2022	South Korea	Oct-2015
Chile	Jul-2019	Indonesia	Jul-2018	Netherlands	May-2015	Spain	May-2015
China	Nov-2020	Ireland	May-2015	New Zealand	Apr-2020	Sri Lanka	Feb-2019
Colombia	Oct-2021	Israel	Jan-2016	Norway	May-2015	Sweden	May-2015
Costa Rica	Apr-2021	Italy	May-2015	Oman	Jan-2021	Switzerland	Aug-2015
Croatia	May-2015	Japan	Mar-2015	Pakistan	Dec-2020	Taiwan	Sep-2016
Cyprus	May-2015	Jordan	Nov-2019	Panama	Mar-2020	Thailand	Mar-2016
Czech Republic	May-2015	Kazakhstan	Apr-2022	Paraguay	Feb-2022	UAE	Feb-2017
Denmark	May-2015	Kuwait	May-2016	Peru	May-2019	UK	May-2015
Ecuador	Jul-2020	Latvia	May-2015	Philippines	Dec-2016	US	Feb-2015

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Lenvima Approval Status Worldwide (Country/ Region)

June, 2022

Thyroid cancer

Vietnam

Jun-2020

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

1st line Renal cell carcinoma

Australia	May-2022	Latvia	Nov-2021	Taiwan	Jan-2022
Austria	Nov-2021	Lebanon	Apr-2022	UK	Nov-2021
Belgium	Nov-2021	Liechtenstein	Nov-2021	US	Aug-2021
Bulgaria	Nov-2021	Lithuania	Nov-2021		
Canada	May-2022	Luxembourg	Nov-2021		
Croatia	Nov-2021	Malta	Nov-2021		
Cyprus	Nov-2021	Netherlands	Nov-2021		
Czech Republic	Nov-2021	New Zealand	Jan-2022		
Denmark	Nov-2021	Norway	Nov-2021		
Estonia	Nov-2021	Philippines	Mar-2022		
Finland	Nov-2021	Poland	Nov-2021		
France	Nov-2021	Portugal	Nov-2021		
Germany	Nov-2021	Romania	Nov-2021		
Greece	Nov-2021	Russia	Mar-2022		
Hungary	Nov-2021	Slovakia	Nov-2021		
Iceland	Nov-2021	Slovenia	Nov-2021		
Ireland	Nov-2021	South Korea	Mar-2022		
Israel	Mar-2022	Spain	Nov-2021		
Italy	Nov-2021	Sweden	Nov-2021		
Japan	Feb-2022	Switzerland	May-2022		

In Europe, lenvatinib is approved under the brand name Kisplyx[®] for treatment of renal cell carcinoma

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Lenvima Approval Status Worldwide (Country/ Region)

June, 2022

2nd line Renal cell carcinoma

Argentina	May-2019	Greece	Aug-2016	Namibia	Mar-2022	Switzerland	Aug-2017
Australia	Jul-2017	Guatemala	Dec-2020	Netherlands	Aug-2016	Taiwan	Jul-2017
Austria	Aug-2016	Hong Kong	Nov-2017	New Zealand	Apr-2020	Thailand	Mar-2018
Belgium	Aug-2016	Hungary	Aug-2016	Norway	Aug-2016	UK	Aug-2016
Bolivia	Dec-2021	Iceland	Aug-2016	Pakistan	Dec-2020	US	May-2016
Brazil	Oct-2018	India	Dec-2019	Panama	Mar-2020		
Brunei	Dec-2018	Ireland	Aug-2016	Paraguay	Feb-2022		
Bulgaria	Aug-2016	Israel	Dec-2016	Peru	May-2019		
Canada	Sep-2017	Italy	Aug-2016	Philippines	Dec-2016		
Chile	Jul-2019	Kazakhstan	Apr-2022	Poland	Aug-2016		
Costa Rica	Apr-2021	Latvia	Aug-2016	Portugal	Aug-2016		
Croatia	Aug-2016	Lebanon	May-2017	Romania	Aug-2016		
Cyprus	Aug-2016	Liechtenstein	Aug-2016	Russia	Sep-2016		
Czech Republic	Aug-2016	Lithuania	Aug-2016	Singapore	May-2017		
Denmark	Aug-2016	Luxembourg	Aug-2016	Slovakia	Aug-2016		
Ecuador	Jul-2020	Macau	Jul-2018	Slovenia	Aug-2016		
Estonia	Aug-2016	Malaysia	Oct-2018	South Africa	May-2020		
Finland	Aug-2016	Malta	Aug-2016	Spain	Aug-2016		
France	Aug-2016	Mexico	Jan-2018	Sri Lanka	Feb-2019		
Germany	Aug-2016	Myanmar	Jun-2019	Sweden	Aug-2016		

In Europe, lenvatinib is approved under the brand name Kisplyx[®] for treatment of renal cell carcinoma

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Lenvima Approval Status Worldwide (Country/ Region)

June, 2022

Hepatocellular carcinoma

Argentina	May-2019	Estonia	Aug-2018	Liechtenstein	Aug-2018	Qatar	Dec-2021
Australia	Sep-2018	Finland	Aug-2018	Lithuania	Aug-2018	Romania	Aug-2018
Austria	Aug-2018	France	Aug-2018	Luxembourg	Aug-2018	Russia	Oct-2018
Bahrain	May-2020	Germany	Aug-2018	Macau	Apr-2019	Saudi Arabia	May-2020
Belgium	Aug-2018	Greece	Aug-2018	Malaysia	Nov-2019	Singapore	May-2019
Bolivia	Dec-2021	Guatemala	Dec-2020	Malta	Aug-2018	Slovakia	Aug-2018
Brazil	Feb-2019	Hong Kong	Feb-2019	Mexico	Apr-2020	Slovenia	Aug-2018
Brunei	Aug-2020	Hungary	Aug-2018	Morocco	Feb-2021	South Africa	May-2020
Bulgaria	Aug-2018	Iceland	Aug-2018	Myanmar	Oct-2019	South Korea	Aug-2018
Canada	Dec-2018	India	Mar-2019	Namibia	Mar-2022	Spain	Aug-2018
China	Sep-2018	Indonesia	Nov-2019	Netherlands	Aug-2018	Sri Lanka	Feb-2019
Chile	Jul-2019	Ireland	Aug-2018	New Zealand	Apr-2020	Sweden	Aug-2018
Colombia	Oct-2021	Israel	Apr-2019	Norway	Aug-2018	Switzerland	Oct-2018
Costa Rica	Apr-2021	Italy	Aug-2018	Oman	Jan-2021	Taiwan	Nov-2018
Croatia	Aug-2018	Japan	Mar-2018	Panama	Mar-2020	Thailand	May-2019
Cyprus	Aug-2018	Jordan	Apr-2020	Paraguay	Feb-2022	UAE	Jun-2019
Czech Republic	Aug-2018	Kazakhstan	Apr-2022	Peru	May-2019	UK	Aug-2018
Denmark	Aug-2018	Kuwait	Nov-2020	Philippines	Oct-2018	US	Aug-2018
Ecuador	Jul-2020	Latvia	Aug-2018	Poland	Aug-2018	Vietnam	Jun-2020
Egypt	Mar-2021	Lebanon	Feb-2019	Portugal	Aug-2018		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

2nd line Endometrial Carcinoma(EC)

Australia	Sep-2019	Japan	Dec-2021	South Korea	May-2020
Austria	Nov-2021	Latvia	Nov-2021	Spain	Nov-2021
Belgium	Nov-2021	Lebanon	Apr-2022	Sweden	Nov-2021
Bulgaria	Nov-2021	Liechtenstein	Nov-2021	Taiwan	Jun-2020
Canada	Sep-2019	Lithuania	Nov-2021	Thailand	Dec-2020
Croatia	Nov-2021	Luxembourg	Nov-2021	UK	Nov-2021
Cyprus	Nov-2021	Macau	May-2021	US	Sep-2019
Czech Republic	Nov-2021	Malaysia	Jul-2020		
Denmark	Nov-2021	Malta	Nov-2021		
Estonia	Nov-2021	Netherlands	Nov-2021		
Finland	Nov-2021	New Zealand	Mar-2022		
France	Nov-2021	Norway	Nov-2021		
Germany	Nov-2021	Philippines	Feb-2020		
Greece	Nov-2021	Poland	Nov-2021		
Hong Kong	Nov-2020	Portugal	Nov-2021		
Hungary	Nov-2021	Romania	Nov-2021		
Iceland	Nov-2021	Russia	Jun-2020		
Ireland	Nov-2021	Singapore	Oct-2020		
Israel	Mar-2022	Slovakia	Nov-2021		
Italy	Nov-2021	Slovenia	Nov-2021		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.